Completed
Adjuvant treatment of high risk uterine leiomyosarcoma with gemcitabine/docetaxel, followed by: a phase II multi-center trial
Type of Sarcoma:
Uterine Leiomyosarcoma
Drug:
Gemcitabine and Docetaxel
Accrual Status:
Closed
Overall Study Principal Investigator:
Martee L. Hensley, MD
Memorial Sloan Kettering Cancer Institute